Sunitinib rechallenge in metastatic renal cell carcinoma patients (pages 5400–5406)
Ivan N. Zama, Thomas E. Hutson, Paul Elson, James M. Cleary, Toni K. Choueiri, Daniel Y.C. Heng, Nikhil Ramaiya, M. Dror Michaelson, Jorge A. Garcia, Jennifer J. Knox, Bernard Escudier and Brian I. Rini
Version of Record online: 2 NOV 2010 | DOI: 10.1002/cncr.25583
The optimal clinical approach to the treatment-resistant renal cell carcinoma patient was unknown, and requires careful prospective trials for further insight. Sunitinib rechallenge had potential benefits in metastatic renal cell carcinoma patients. Prospective studies to evaluate this strategy were needed.